Cancer-associated driver mutations in KRAS lock the protein into the GTP-bound state preventing the hydrolysis of GTP to GDP, resulting in constitutive signaling which give mutated cells a growth advantage and leads to development of cancer [5–8]. This evidence concerns the gene KRAS and cancer.